Chronic Kidney Disease Clinical Trial
Official title:
Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease
To measure oxycodone's intradialytic mass transfer rate coefficient and oxycodone's removal rate using an ODE/PDE hemodialysis model. To implement a rational clinical strategy for estimating a patient's post-hemodialysis oxycodone restoration dose using results from an ODE/PDE model of hemodialysis.
Clinical Trial Simulation Design and Investigational Plan: Our study sample will consist of
a group of 10 randomly selected virtual Caucasian hemodialysis patients with Stage 5 chronic
kidney disease (CKD) and a group of 10 randomly selected Caucasian age and weight matched
healthy controls. Patients, 5 women and 5 men in each group, will be synthesized using
clinical trial simulation techniques from the case report data reported by Lee, Leng, and
Cooper and the experiments by Kirvela and coworkers. Our goal is to learn about the
populations from which the study samples are drawn. To meet this goal, the investigators
will perform Monte Carlo simulation.
Both virtual control subjects and experimental hemodialysis patients meeting all
inclusion/exclusion criteria will be studied in two phases.
In phase 1, subjects will receive a ceiling dose of controlled-release oxycodone
hydrochloride (hereafter CR-OC) totaling 40 mg twice daily for 2 weeks prior to the
experimental hemodialysis procedure on day 15. Because patients in the hemodialysis group
will be anuric, they will undergo hemodialysis three times weekly.10 During that time, they
will receive supplemental oral immediate-release oxycodone every 4 h as needed to control
their pain up to a visual analog scale level of < 3. These pain levels would correspond with
plasma oxycodone concentrations of 20-50 ng/mL.
Patients will be instructed to take their last dose of CR-OC 2 to 3 hours before starting
the experimental hemodialysis procedure. This dosing schedule will ensure that the time to
CR-OC's maximum concentration (Tmax) and its maximum concentration (Cmax) will be reached at
the time of blood sampling at t = 0, enabling accurate assessment of CR-OC's elimination
with negligible influence from absorption or redistribution.
At 8:00 am on the 15th day, and this is phase 2 of the study, each individual will undergo
hemodialysis for 4 hours. Two independent simultaneous blood samples for measurement of
plasma oxycodone concentrations from both arterial inflow (Cin) and venous outflow (Cout)
sites will be obtained immediately upon starting hemodialysis (t = 0) and immediately after
hemodialysis before shutting off the machine (t = 4). For all calculations and ODE/PDE
modeling (see Model Diagram), the oxycodone concentrations from those samples will be
combined and averaged. Oxycodone's intradialytic extraction ratio will be calculated from
the simultaneously sampled arterial (inflow) and venous (outflow) plasma oxycodone
concentrations by dividing their difference by the arterial plasma oxycodone concentrations.
Controls will eat three light meals and a bedtime snack daily. Hemodialysis patients will
eat a standard renal diet. Foods will be free of known inhibitors of CYP2D6. Individuals
will be digitally abstained from nicotine, caffeine, grapefruit juice and alcohol during the
course of the study.
;
Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Basic Science
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05491642 -
A Study in Male and Female Participants (After Menopause) With Mild to Moderate High Blood Pressure to Learn How Safe the Study Treatment BAY3283142 is, How it Affects the Body and How it Moves Into, Through and Out of the Body After Taking Single and Multiple Doses
|
Phase 1 | |
| Recruiting |
NCT06363097 -
Urinary Uromodulin, Dietary Sodium Intake and Ambulatory Blood Pressure in Patients With Chronic Kidney Disease
|
||
| Terminated |
NCT04043026 -
The Effects of Renal Function and Atrial Fibrillation on Lipoproteins and Clot Structure/Function
|
||
| Completed |
NCT05318014 -
Low-protein Formula Supplements in Chronic Kidney Disease
|
N/A | |
| Active, not recruiting |
NCT06071065 -
Clinical Pharmacist Intervention on Medication Adherence and Clinical Outcomes in Chronic Kidney Disease Patients
|
N/A | |
| Completed |
NCT02878317 -
Skin Autofluorescence as a Risk Marker in People Receiving Dialysis.
|
||
| Not yet recruiting |
NCT06039254 -
Safety and Pharmacokinetics of HRS-1780 in Healthy Subjects and Subjects With Impaired Renal Function
|
Phase 1 | |
| Recruiting |
NCT03160326 -
The QUALITY Vets Project: Muscle Quality and Kidney Disease
|
||
| Completed |
NCT02836574 -
A Study of Renal Autologous Cell Therapy (REACT) in Type 2 Diabetics With Chronic Kidney Disease
|
Phase 2 | |
| Completed |
NCT02756520 -
Observational Study on CKD Treatment With a Ketosteril Supplemented Protein-restricted Diet (Keto-024-CNI)
|
||
| Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
| Withdrawn |
NCT02885545 -
The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial
|
Phase 4 | |
| Completed |
NCT02896309 -
The Effect of Correction of Metabolic Acidosis in CKD on Intrarenal RAS Activity
|
N/A | |
| Completed |
NCT02875886 -
DD-study: Diet or Diuretics for Salt-sensitivity in Chronic Kidney Disease
|
Phase 4 | |
| Active, not recruiting |
NCT02483039 -
Nephrologist Follow-up Versus Usual Care After an Acute Kidney Injury Hospitalization
|
N/A | |
| Completed |
NCT02992548 -
Effect of Pravastatin on Erythrocyte Membrane Fatty Acid Contents in Patients With Chronic Kidney Disease
|
Phase 4 | |
| Completed |
NCT02369549 -
Micro-Particle Curcumin for the Treatment of Chronic Kidney Disease
|
Phase 3 | |
| Terminated |
NCT02543177 -
Optimised Procedure in Patients With NSTEMI and CKD
|
N/A | |
| Recruiting |
NCT02205944 -
Impact of Presurgical Exercise on Hemodialysis Fistula Outcomes
|
N/A | |
| Active, not recruiting |
NCT02231138 -
Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease
|
Phase 4 |